Default company panoramic image
Cd2fee7b b1a7 4656 aa50 6db5c67ee6d3

Hurel Corporation

Hurel is a private, revenue-generating medtech company that uses cell biology and microfluidics to help drug companies predict early (i.e., pre-clinically) the

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location New Brunswick, NJ, USA
  • Currency USD
  • Employees 6
  • Website hurelcorp.com

Company Summary

- Hurel Corporation utilizes cell biology and microfluidics to better predict the effects of pharmaceuticals and chemicals on the human body.
- Hurel’s patented, in vitro testing platforms provide superior means to evaluate the performance of a drug in humans before researchers make the costly, risky decision whether or not to invest in human clinical trials.
- Recognized as a highly promising alternative to animal testing.

Team

  • Default avatar
    Robert M. Freedman
    Chairman and CEO

    Robert M. Freedman, Chairman & CEO, has piloted Hurel through its early development to
    the launch of its first commercial product. Previously he was a member of the venture capital
    firms BancBoston Ventures & Wolfensohn Partners. He was also a First Vice President in the
    firm Drexel Burnham Lambert. Rob holds an SB Degree from MIT and
    Masters’ Degrees from the Kennedy School of Government at Harvard and (with honors) from Harvard Business Sch

  • Default avatar
    Martin Yarmush, M.D., Ph.D.
    Chief Scientific Advisor

    Internationally known engineer of cell cultures in microfluidic systems. Founder/Director, Center for Engineering in Medicine, Massachusetts General Hospital. Founder/Professor, School of Biomedical engineering, Rutgers. Ph.D., Rockefeller (biophysical chemistry); Ph.D., MIT (chemical engineering); M.D., Yale

  • Default avatar
    James MacDonald, Ph.D., DABT
    Director of Corporation

    Formerly EVP of pre-clinical development, Schering-Plough. Has taken hundreds of drug candidates into development, >30 of which have become major drugs. Ph.D., University of Cincinnati.

  • Default avatar
    Laura Dike
    Head of Operations

    Formerly Operations Manager, BD Biosciences, 10 years' experience in Biotech R&D/Operations management. Expertise in hepatocyte culture, DMPK, cellular assay systems, GLP. BA, Wellesley; Ph.D., Boston University School of Medicine. (to be employed upon completion of financing)

  • Default avatar
    Leslie Z. Benet, Ph.D.
    Scientific Advisory Board Chairman

    Professor and former Chairman, Department of Pharmaceutical Sciences, UCSF. Founder and first President, American Association of Pharmaceutical Scientists. Member, Institute of Medicine; seven doctorates honoris causa. Most widely cited pharmacokineticist in the world. SB and MS, University of Rochester; Ph.D., UCSF.

  • Default avatar
    Eric Novik
    Chief Technology Officer

    Laboratory expert in Hurel Static- and Hurel Flow-based systems; advanced tissue culture, stem cells, DMPK and tox assays and applications. Ph.D. (biomedical engineering), Rutgers University

Advisors

  • Default avatar
    Dykema Gossett PLLC, Los Angeles (Corporate Securities); Arrigo And Scott Lee, LLP, Washington D.C. (IP)
    Lawyer
    Unconfirmed
    Default avatar
    Gaytan & Leevan, LLP, Los Angeles
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    - seed investor: Athena Capital Partners, LLC.
    Unconfirmed
    Default avatar
    - convertible notes: aggregate face value $1,085k issued to accredited individual
    Unconfirmed
    Default avatar
    investors in amounts up to $200k each.
    Unconfirmed